Krízová P, Vlcková J, Bobák M
Národní referencní laborator pro meningokokové nákazy, Státní zdravotní ústav, Praha.
Epidemiol Mikrobiol Imunol. 1995 Mar;44(1):9-14.
In the Czech Republic where meningococcal disease occurred only sporadically for a very long period and Neisseria meningitidis B prevailed, the use of a meningococcal polysaccharide vaccine was never indicated. This situation changed in 1993 when a new clone of Neisseria meningitidis C:2a:P1.2(P1.5) appeared in the Czech Republic, found to be responsible for a new epidemiological and clinical situation. The disease caused by this new clone is more serious, showing a high fatality rate (20%) and frequently an atypical clinical course. In May 1993, the highest age-specific incidence in the most affected locality was established in the age group of 15-19 years (52.1/100,000), while in the whole Czech Republic the respective figure was 2.4. A vaccination campaign focusing on the most affected age group started in this locality at the beginning of June 1993, using a polysaccharide meningococcal vaccine A+C (Mérieux). During two weeks 6191 students of the age group of 15-19 years were vaccinated, i.e. 96% of all students of this age group, 64.5% of the population 15-19 years old and 5.6% of the whole population of this locality. This age targeted vaccination prevented the spread of the meningococcal invasive disease caused by Neisseria meningitidis C in this locality. The decrease in morbidity in this locality is statistically highly significant (p < 0.001). In another affected locality, where vaccination was not age targeted and showed a very low coverage, the incidence of the invasive disease caused by Neisseria meningitidis C did not decrease. During the following period (1993-1994) the new meningococcal clone spread to all regions of the Czech Republic. Active surveillance of meningococcal invasive disease has been conducted with the aim to recognize as early as possible an emerging epidemiological indication for targeted vaccination.
在捷克共和国,很长一段时间内脑膜炎球菌病仅偶尔发生,且以B群脑膜炎奈瑟菌为主,因此从未有过使用脑膜炎球菌多糖疫苗的指征。1993年情况发生了变化,当时一种新的C群脑膜炎奈瑟菌克隆株C:2a:P1.2(P1.5)在捷克共和国出现,发现它导致了一种新的流行病学和临床情况。由这种新克隆株引起的疾病更为严重,显示出高死亡率(20%),且临床病程常常不典型。1993年5月,在受影响最严重的地区,15至19岁年龄组的年龄别发病率最高(52.1/10万),而在整个捷克共和国,相应数字为2.4。1993年6月初,在该地区针对受影响最严重的年龄组开展了一场疫苗接种运动,使用的是A+C群多糖脑膜炎球菌疫苗(默克公司生产)。在两周内,15至19岁年龄组的6191名学生接种了疫苗,即该年龄组所有学生的96%、15至19岁人口的64.5%以及该地区总人口的5.6%。这种针对年龄的疫苗接种预防了该地区由C群脑膜炎奈瑟菌引起的脑膜炎球菌侵袭性疾病的传播。该地区发病率的下降在统计学上具有高度显著性(p<0.001)。在另一个受影响的地区,疫苗接种未针对年龄且覆盖率很低,由C群脑膜炎奈瑟菌引起的侵袭性疾病发病率并未下降。在随后的时期(1993 - 1994年),新的脑膜炎球菌克隆株传播到了捷克共和国的所有地区。已对脑膜炎球菌侵袭性疾病进行了主动监测,目的是尽早识别出有针对性疫苗接种的新出现的流行病学指征。